| ||||||||||||||||||||||||||||||||||||||||||||||||||||
1 October 1994 | Volume 121 Issue 7 | Page 550
In her review article [1], Dr. French mentions osteoporosis that is treatable with vitamin D as a long-term consequence of phenytoin therapy. In fact, osteomalacia with hypocalcemia and elevated alkaline phosphatase levels is far more common. This condition is attributed to both altered metabolism of vitamin D and the inhibition of intestinal absorption of Ca++ [2]. Phenytoin also increases the metabolism of vitamin K and reduces the concentration of vitamin K-dependent proteins that are important for normal Ca++ metabolism [3]. This may explain why osteomalacia is not always ameliorated by the administration of vitamin D. Phenytoin may block the effect of the parathyroid hormone on bone, inducing a type of pseudohypoparathyroidism [4], with resulting bone and teeth changes.
1. French J. The long-term therapeutic management of epilepsy. Ann Intern Med. 1994; 120:411-22.
2. Goodman LS, Gilman AG. The Pharmacological Basis of Therapeutics. 8th ed. New York: Macmillan; 1990:442.
3. Keith DA, Gundberg GM, Japour A, Aronoff J, Alvarez N, Gallop PM. Vitamin K dependent proteins and anticonvulsant medication. Clin Pharmacol Ther. 1983; 34:529-32.
4. Harris M, Goldhaber P. Root abnormality in epileptics and the inhibition of parathroid hormone-induced bone resorption by diphenylhydantoin in tissue culture. Arch Oral Biol. 1974; 19:981. About Letters
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
LETTER
Osteomalacia and Phenytoin Therapy
TO THE EDITOR:
References
![]()
Top
References
![]()
Include no more than 300 words of text, three authors, and five references
Type with double-spacing
Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
This article has been cited by other articles:
![]() |
J. L. Walker, P. A. Crock, S. N. Behncken, S. W. Rowlinson, L. M. Nicholson, T. J. C. Boulton, and M. J. Waters A Novel Mutation Affecting the Interdomain Link Region of the Growth Hormone Receptor in a Vietnamese Girl, and Response to Long-Term Treatment with Recombinant Human Insulin-Like Growth Factor-I and Luteinizing Hormone-Releasing Hormone Analogue J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2554 - 2561. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||